백신 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Vaccines Market was valued at USD 76.4 billion in 2024 and is estimated to grow at a CAGR of 7.1% to reach USD 145.8 billion by 2034. This growth is largely propelled by the continuous emergence of infectious diseases such as hepatitis, seasonal influenza, and novel virus strains. As these diseases remain a constant threat to public health, governments and health organizations are ramping up immunization efforts to reduce infection rates. Supportive public initiatives, increasing healthcare budgets in developing regions, and advancements in vaccine R&D continue to shape a favorable environment for expansion. Additionally, the global rise in combination vaccines, which deliver immunity for multiple diseases through a single dose, is accelerating innovation and simplifying immunization protocols.

Development of next-generation vaccines targeting complex conditions such as cancers, chronic infections, and autoimmune diseases is expanding the market's therapeutic scope. A growing aging population, especially across developed nations, remains highly susceptible to infections, further fueling global vaccine demand. Strong collaborations between private firms and public health bodies, coupled with evolving technologies such as mRNA and recombinant protein platforms, are enhancing vaccine efficacy, delivery, and accessibility. Collectively, these factors are reinforcing long-term market momentum.

In 2024, subunit vaccines segment was valued at USD 37.6 billion and is estimated to reach USD 70.7 billion by 2034, growing at a CAGR of 6.9%. These vaccines include recombinant, polysaccharide, and conjugate types, each contributing to heightened immunogenicity without using whole pathogens. Their ability to target specific proteins from disease-causing organisms improves safety profiles and reduces unwanted immune responses. The segment continues to gain traction due to its T cell-dependent immune activation, which promotes stronger memory responses, long-lasting protection, and suitability for vulnerable populations like infants and young children.

The viral diseases segment held 66.2% share in 2024 and is expected to maintain strong growth through 2034. The category comprises vaccines for hepatitis, influenza, HPV, rotavirus, herpes zoster, MMR, COVID-19, and other viruses. As awareness and prevention efforts have expanded, immunization programs have scaled globally, improving coverage and access. Recent advancements in manufacturing platforms like mRNA and subunit technologies have enhanced rapid-response capabilities during viral outbreaks, supporting robust public health strategies worldwide and increasing uptake across all age groups.

North America Vaccines Market generated USD 32.3 billion in 2024 and is expected to reach USD 59.3 billion by 2034 at a CAGR of 6.6%. The region's leadership stems from its comprehensive healthcare infrastructure, ongoing public immunization campaigns, and significant investment in preventive care. Consistent policy-level initiatives, high levels of awareness, and strong demand for vaccines targeting HPV and other viral threats continue to drive sales. The U.S. has implemented widespread school-based programs and adult immunization drives, enhancing access and compliance across population segments.

Key manufacturers contributing to the competitive dynamics of the Global Vaccines Market include Sanofi, Serum Institute of India, Valneva, CSL Seqirus, Emergent Biosolutions, Pfizer, Moderna, Novavax, GlaxoSmithKline (GSK), AstraZeneca, Biofarma, Sinovac, Bharat Biotech, Haffkine Bio-Pharmaceutical, VBI Vaccines, and Merck. Leading companies in the vaccines sector are actively advancing their pipelines through sustained investments in R&D, particularly in novel platforms like mRNA, recombinant subunits, and vector-based formulations.

Partnerships and joint ventures with biotech firms, academic institutions, and government health agencies are helping expedite development and regulatory clearance for next-gen vaccines. Firms are also expanding production capabilities globally to ensure rapid scalability during outbreaks and to serve underserved markets efficiently. Strategic product diversification, including development of combination and therapeutic vaccines, is helping companies address broader disease burdens.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Vaccine type
  • 2.2.3 Disease type
  • 2.2.4 Age group
  • 2.2.5 End use
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of infectious disease
    • 3.2.1.2 Growing immunization coverage programs
    • 3.2.1.3 Increasing pediatric population in developing economies
    • 3.2.1.4 Advancements in vaccine formulation and production efficiency
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory approval processes
    • 3.2.2.2 High cost of storage and transportation of vaccine
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expanding public-private partnerships for vaccine distribution
    • 3.2.3.2 Growing focus on combination vaccines
• 3.3 Growth potential analysis
• 3.4 Technology landscape
• 3.5 Pipeline analysis
• 3.6 Regulatory landscape
• 3.7 Future market trends
• 3.8 Porter’s analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 Expansion plans

Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2021-2034 ($ Mn)

• 5.1 Key trends
• 5.2 Subunit vaccines
  • 5.2.1 Recombinant vaccines
  • 5.2.2 Conjugate vaccines
  • 5.2.3 Polysaccharide vaccines
• 5.3 Toxoid vaccines
• 5.4 Inactivated vaccines
• 5.5 Live attenuated vaccines
• 5.6 Other vaccine types

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021-2034 ($ Mn)

• 6.1 Key trends
• 6.2 Viral diseases
  • 6.2.1 Hepatitis
  • 6.2.2 Influenza
  • 6.2.3 HPV
  • 6.2.4 Measles, mumps, and rubella (MMR)
  • 6.2.5 Rotavirus
  • 6.2.6 Herpes zoster
  • 6.2.7 Covid-19
  • 6.2.8 Other viral diseases
• 6.3 Bacterial diseases
  • 6.3.1 Meningococcal diseases
  • 6.3.2 Pneumococcal diseases
  • 6.3.3 DPT
  • 6.3.4 Other bacterial diseases

Chapter 7 Market Estimates and Forecast, By Age Group, 2021-2034 ($ Mn)

• 7.1 Key trends
• 7.2 Pediatric
• 7.3 Adult

Chapter 8 Market Estimates and Forecast, By End Use, 2021-2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
  • 8.2.1 Public
  • 8.2.2 Private
• 8.3 Specialty clinics
• 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021-2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 AstraZeneca
• 10.2 Bharat Biotech
• 10.3 Biofarma
• 10.4 CSL Seqirus
• 10.5 Emergent Biosolutions
• 10.6 GlaxoSmithKline (GSK)
• 10.7 Haffkine Bio-Pharmaceutical
• 10.8 Merck
• 10.9 Moderna
• 10.10 Novavax
• 10.11 Pfizer
• 10.12 Sanofi
• 10.13 Serum Institute of India
• 10.14 Sinovac
• 10.15 Valneva
• 10.16 VBI Vaccines